TY014  Anti-Yellow Fever Monoclonal Antibody

TY014 will be the first therapeutic in the world explicitly targeting Yellow Fever Virus (YFV) to enter clinical trials. It is anticipated that a monoclonal antibody therapeutic could be administered to infected cases to reduce disease severity within the patient and their contacts. TY014 is a fully engineered human IgG1 monoclonal antibody against the yellow fever virus manufactured with ovary cells. It targets a conserved epitope on the yellow fever virus envelope (E) protein. 

TY014  Anti-Yellow Fever Monoclonal Antibody Indication

TY014 is indicated as a postinfection intravenously therapy for yellow fever virus infection.

TY014  Anti-Yellow Fever Monoclonal Antibody News

July 30, 2020 - Phase 1 Trial of a Therapeutic Anti–Yellow Fever Virus Human Antibody. This phase 1 trial of TY014 did not identify worrisome safety signals and suggested potential clinical benefit, which requires further assessment in a phase 2 trial. 

November 18, 2019 - "Our successful trials pave the way for a potential first-in-class treatment for Yellow Fever. This rapid development following the similar achievement for Zika affirms the exciting collaboration between Tychan and WuXi Biologics to enable a new paradigm to expedite biologics development initiatives to address emerging infectious disease outbreaks and eventually potentially expand to other therapeutics," said Teo Ming Kian, Chairman of the Board, Tychan.

TY014  Anti-Yellow Fever Monoclonal Antibody Clinical Trials

Clinical Trial NCT03776786: Phase 1 Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans